Halozyme Therapeutics, Inc.
HALO
Clasificación en acciones
#1532
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Precio por acción
$125.31
Capitalización bursátil
$14.22B
Cambio (1 día)
0.76%
Cambio (1 año)
87.37%
País
US
Comercio Halozyme Therapeutics, Inc. (HALO)
Categoría
Healthcare
Ingresos de Halozyme Therapeutics, Inc. (HALO)
Ingresos en Jun 2026 TTM: $1.66B
Según los últimos informes financieros de Halozyme Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son $1.66B. En 2023, la empresa obtuvo unos ingresos de $829.25M un aumento con respecto a los ingresos del año 2022, que fueron de $660.12M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Halozyme Therapeutics, Inc. desde 2001 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.66B | 63.86% |
| 2024 | $1.02B | 22.44% |
| 2023 | $829.25M | 25.62% |
| 2022 | $660.12M | 48.91% |
| 2021 | $443.31M | 65.67% |
| 2020 | $267.59M | 36.53% |
| 2019 | $195.99M | 29.06% |
| 2018 | $151.86M | -52.04% |
| 2017 | $316.61M | 115.84% |
| 2016 | $146.69M | 8.61% |
| 2015 | $135.06M | 79.28% |
| 2014 | $75.33M | 37.47% |
| 2013 | $54.80M | 29.47% |
| 2012 | $42.33M | -24.54% |
| 2011 | $56.09M | 311.67% |
| 2010 | $13.62M | -0.35% |
| 2009 | $13.67M | 55.99% |
| 2008 | $8.76M | 130.66% |
| 2007 | $3.80M | 287.02% |
| 2006 | $981.75K | 671.76% |
| 2005 | $127.21K | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | $25.71K | -70.71% |
| 2002 | $87.77K | 255.56% |
| 2001 | $24.69K | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 658.79% |
US
|
|
| $2.23B | 33.92% |
US
|
|
| $15.74B | 846.32% |
AU
|
|
| $6.02B | 261.91% |
NL
|
|
| - | - |
CH
|
